Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...

The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...

Revolutionizing CGM Accessibility and Performance Trinity Biotech’s redesigned ergonomic modular CGM system is designed with affordability, accuracy, and sustainability in mind. The device’s ...

(MENAFN- GlobeNewsWire - Nasdaq) Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Feb. 06, 2025 (GLOBE ...

Trinity Biotech (TRIB) announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

Trinity Biotech's next-generation CGM system includes reusable and rechargeable components, aiming to make the technology more affordable and environmentally friendly. This development could ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

Revolutionizing CGM Accessibility and Performance Trinity Biotech’s redesigned ergonomic modular CGM system is designed with affordability, accuracy, and sustainability in mind. The device’s reusable ...